MTOR and extranodal nasal NK/T cell lymphoma: In a study by Kawada et al., mTOR inhibitors (rapamycin and CCI-779) arrested NKTCL cells in the G1 phase and reduced cell viability [103], suggesting that mTOR inhibitor may also be a potential therapeutic option in NKTCL treatment.